1. Abelson HT, Rabstein LS (1970) Lymphosarcoma: virus- induced thymic-independent disease in mice. Cancer Res 30:2213–2222
2. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds) (2010) SEER cancer statistics review, 1975–2007, National Cancer Institute. Bethesda. http://seer.cancer.gov/csr/1975_2007/ , based on November 2009 SEER data submission, posted to the SEER web site
3. Apperley J (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8:1018–1029
4. Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV (2005) BCR-ABL expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 65:8912–8919
5. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ (1994) Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83:2038–2044